Compare Adaptive Biotechnologies Corp (ADPT) vs Comcast Corporation (CMCSA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Comcast Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $20.24 (market cap $3.33B), while Comcast Corporation trades at $23.35 (market cap $83.63B). The key difference: Comcast Corporation is far larger — about 25.1× Adaptive Biotechnologies Corp's market cap, and Comcast Corporation pays a 5.64% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CMCSA | |
|---|---|---|
Market Cap | $3.33B | $83.63B |
Sector | Health | Media |
52-Week High | $22.37 | $34.01 |
52-Week Low | $10.24 | $22.32 |
Enterprise Value | $3.19B | $168.77B |
Dividend Yield | — | 5.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
CMCSA trades at $23.41, down 1.6% over 24 hours, with a bearish technical signal but strong fundamentals including a low P/E of 4.66 and net income margin of 15%. Recent news highlights the planned spin-off of NBCUniversal and Sky's acquisition of ITV's media unit for $2.14 billion, signaling strategic refocusing on broadband infrastructure.
The stock appears undervalued with a consensus price target of $31.07, offering 33% upside, but faces risks from execution of corporate restructuring and pay-TV decline. Positive earnings beats and robust cash flow support a favorable outlook, though investor sentiment is mixed amid spin-off uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →
